Carneiro et al., 2016 - Google Patents
Is personalized medicine here?Carneiro et al., 2016
- Document ID
- 12351370130352363729
- Author
- Carneiro B
- Costa R
- Taxter T
- Chandra S
- Chae Y
- Cristofanilli M
- Giles F
- Publication year
- Publication venue
- Oncology
External Links
Snippet
Major technologic advances in genomics have made possible the identification of critical genetic alterations in cancer, which has led to a rapid paradigm shift in what is now considered personalized cancer treatment. This exponential growth in the understanding of …
- 239000003814 drug 0 title description 60
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sartore-Bianchi et al. | Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | |
Taber et al. | Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis | |
Berger et al. | The emerging clinical relevance of genomics in cancer medicine | |
Rodrigues et al. | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer | |
Senft et al. | Precision oncology: the road ahead | |
Meric-Bernstam et al. | A decision support framework for genomically informed investigational cancer therapy | |
Radovich et al. | Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers | |
Collins et al. | Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics | |
Le Tourneau et al. | Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials | |
Roychowdhury et al. | Translating cancer genomes and transcriptomes for precision oncology | |
Coyne et al. | Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH | |
Kurnit et al. | Precision oncology decision support: current approaches and strategies for the future | |
Ma et al. | Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer | |
Bryce et al. | Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery | |
Syn et al. | Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review | |
MacConaill et al. | Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges | |
Park et al. | Next-generation sequencing in the clinic | |
Groisberg et al. | The role of next-generation sequencing in sarcomas: evolution from light microscope to molecular microscope | |
Carneiro et al. | Is personalized medicine here? | |
Hempel et al. | Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients | |
Xue et al. | Changing paradigm of cancer therapy: precision medicine by next-generation sequencing | |
Lee et al. | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer | |
Sinn et al. | TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: Next-generation sequencing results from the CONKO-001 trial | |
Weiss et al. | Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making | |
Edsjö et al. | Precision cancer medicine: Concepts, current practice, and future developments |